Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML

Kura Oncology, Inc.

2022-FY EPS reported -$2.03

Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.
Ziftomenib Phase 1: 30% CR rate among 20 NPM1-mutant AML patients at 600 mg recommended Phase 2 dose.
Registration-directed trial KOMET-001 dosed multiple patients; 85-patient enrollment target in US and Europe.
FDA cleared IND for KO-2806, next-generation farnesyl transferase inhibitor; Phase 1 trial expected Q3 2023.
Bristol Myers Squibb made $25M strategic equity investment at $18.25/share; appointed member to steering committee.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.